Mclean Hospital

In the Media: Esketamine Effective and Costly Treating Treatment-Resistant Depression

July 14, 2020

HCP Live

Dr. Eric L. Ross and collaborators examine the cost-effectiveness of esketamine, a novel intranasally dosed antidepressant for patients with treatment-resistant depression.

Read Full Article
 
Journalist or member of the media?Media Contact

Topics

Depression Ketamine

You May Also Like

Alcohol Use on the Rise as Pandemic Continues Into Holiday Season

McLean’s Guide to Managing Mental Health Around the Holidays

Brandon Marshall Tries to Break the Stigma of Mental Illness

Social Media or Social Exclusion – An Interview With Dr. Sperling

More

Resources

In the Media
Media Contact
News
Experts

Latest Videos

Graphic of two brain neurons connecting with black and red purple background.

Autologous iPSC Based Cell Therapy for Parkinson’s Disease

Nurse talking to a man and holding a clipboard.

Why Words Matter in Mental Health Care

Kids on couch eating popcorn and watching a movie.

Mental Wellness for Kids and Teens

African American couple holding hands.

Impact of Racial Discrimination and Trauma on Racial Health Disparities in African American...

More
Videos

Back to top